---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Brexucabtagene Autoleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/brexucabtageneautoleucel
version: v1
---

# Brexucabtagene Autoleucel - NCI

# Brexucabtagene Autoleucel

Placeholder slot

(brek-suh-KAB-tuh-jeen AW-toh-LOO-sel)

This page contains brief information about brexucabtagene autoleucel
(Tecartus) and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Tecartus

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022&audience=consumer)

## Use in Cancer

Brexucabtagene autoleucel
is approved to treat adults with:

- **[mantle cell lymphoma](/Common/PopUps/popDefinition.aspx?id=445048&version=Patient&language=English)** that has come back or does not respond to treatment¹
- **[precursor B lymphoblastic leukemia](/Common/PopUps/popDefinition.aspx?id=524192&version=Patient&language=English)** (a type of [acute lymphoblastic leukemia](/Common/PopUps/popDefinition.aspx?id=45586&version=Patient&language=English)) that has come back or does not respond to treatment

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that brexucabtagene autoleucel provides a clinical benefit in these patients.

Brexucabtagene autoleucel is only available as part of a special program called Tecartus REMS ([Risk Evaluation and Mitigation Strategies](https://www.yescartatecartusrems.com/)).

Brexucabtagene autoleucel
is also being studied in the treatment of other types of
cancer.

## More About Brexucabtagene Autoleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/802259) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Brexucabtagene Autoleucel](https://medlineplus.gov/druginfo/meds/a620054.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Understanding the Risk of Second Cancers After CAR T-Cell Therapy](https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[T-cell Transfer Therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)

[CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Brexucabtagene Autoleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C170439) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
